Ficerafusp Alfa

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameFicerafusp Alfa
Drug Alias NameBCA-101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-TGF-βEGFR T790M inhibitors
TargetsTransforming growth factor betaEGFR T790M
Therapy Area/IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsAnus Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBicara Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBicara Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsAnus Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A